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BCR-ABL Antisense Oligodeoxyribonucleotides Suppress the Growth of Leukemic and Normal Hematopoietic Cells by a Sequence-Specific But Nonantisense Mechanism
By J.L. Vaerman, C. Lammineur, P. Moureau, P. Lewalle ODNs compared with a small number of control ODNs. Many biologic effects of ODNs cannot be attributed to antisense m e~h a n i s m s , 2~*~~ but rather to the toxicity of the degradation products of ODNs or to the (non)specific binding of antisense ODNs to nontargeted RNA, small molecules, or proteins. Therefore, concluding to an antisense effect on the basis of the lack of toxicity of a small number of control ODNs may be questionable. To examine this problem, we investigated the effect of several phosphodiester anti-BCW ABL antisense or control ODNs on the proliferation of CML cell lines. This study was next extended to bone marrow cells. and methylphospho-
MATERIALS AND METHODS
ODNs. Phosphodiester ODNs (Table  l) were synthesized on an automated DNA synthesizer (Cyclone Plus DNA synthesizer or Expedite 8909 DNA/RNA synthesizer; MilliGeniBiosearch, Millipore, Burlington, MA) using the 0-cyanoethyl phosphoramidite chemistry, according to the manufacturer's protocols. After synthesis, the ODNs were cleaved from their solid support and deblocked in 30% ammonium hydroxide at 55°C for 16 hours. The ODNs were purified by anion exchange chromatography2 ' of several bases at any other position within the sequence of the active ODNs do not suppress the observed effect. Similar experiments on normal or CML CD34' cell fraction led to the same observations. We conclude that the antiproliferative effect of the phosphodiester BCR/ABL antisense ODNs cannot be attributed to an antisense mechanism but rather to a nonelucidated effect of a 3' terminal TAT sequence. This effect is not CML specific.
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procedure described above. The ODNs were stored in water at -20°C.
HPLC analysis. HPLC analysis was performed on a Waters instrument equipped with a 625 PEEK solvent delivery system, a 717 autosampler, a 486 UV detector set to 260 nm, and a Nec powermate 386 33i computer (Boxborough, MA). The Millenium 2.0 software (Waters) was used to drive the instruments and to analyze the chromatograms. The samples were chromatographied on an anion exchange column (GEN-PAK FAX; Waters) using a gradient of NaCl (3 mmofi NaCVmin) in 25 mmolL Tris-HC1, pH 8.0, with a flow of 0.75 mL/min. The duration of the gradient (typically 30 minutes) and the salt concentration at the start of elution (typically 300 mmoU L NaCl) were adapted to the investigated samples.
Kinetics of ODN degradation in cell culture media. Phosphodiester ODNs were incubated at 37°C at a concentration of 25 pmolL in RPMI 1640 medium (GIBCO-BRL, Scotland, UK) containing various concentrations of fetal calf (GIBCO-BRL) or human serum. Samples were collected at various time intervals of incubation. After addition of an internal standard (a 20-mer phosphodiester ODN was used for this purpose), the samples were stored immediately at -20°C. Before HPLC analysis (see conditions above), the crude samples were extracted three times using phenol-chloroform. The area of each chromatographic signal (measured at 260 nm) was normalized to the area of the internal standard.
Cell lines. The human cell lines BV173,28 KCL22,29 LAMA84,30 K562," HL60,32 and KYO133 were maintained by serial passages (twice weekly) in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mmol/L glutamine (GIBCO-BRL), 5 pg/mL streptomycin (Diamant, Compibgne, France), and 50 IU/mL penicillin (Continental Pharma, Bruxelles, Belgium). Cells were incubated at 37°C in 100-mL tissue culture flasks in humidified atmosphere with 5% COz. The cell lines were controlled (Table 2) by reverse transcription-polymerase chain reaction (RT-PCR) for the expression of the normal ABL and BCR genes and the BCWABL fusion gene, as already described.34 ODN treatment of cell lines. Cells in their exponential phase of growth were washed with RPM1 1640 medium. Cells were then resuspended in RPMI 1640 medium containing 2.5% human serum at a concentration of lo5 cells/mL. The cell suspension was distributed into 2-mL aliquots. The lyophilized ODNs (20 to 100 nmol) were dissolved in the 2-mL cell suspensions. The viable cell number was determined every 24 hours on 100 pL aliquots from the 2-mL cell suspensions using a trypan blue dye exclusion test in a Burker hemocytometer. The control consisted of cells undergoing the same procedure without any addition of ODN.
Separation of normal and CML CD34+ cell fraction. Bone marrow cells from 5 healthy donors and periferal blood cells from 3 CML patients in chronic phase (2 with a B2A2 and 1 with a B3A2 junction as determined by PCR34) were separated by density centrifugation at 600g using a lymphocyte separation medium (International Medical Belgium, Brussels, Belgium). The samples were enriched in CD34+ cells using a Ceprate LC34 column (CellPro, Bothell, WA) according to the manufacturer's instructions. The CD34' fractions were resuspended in RPMI 1640 medium containing 2.5% human serum, 2 mmol/L L-glutamine, 50 ng/mL recombinant human interleukin-3 (rhuIL-3; Sandoz, Basel, Switzerland), 20 ng/mL rhu-SCF (Immunex, Seattle, WA), and 100 ng/mL rhu-L6 (Sandoz) at a cell concentration of io5 cell/&. The cell suspensions were then distributed into 2-mL aliquots that were used for the ODR incubation experiments. ODN treatment of marrow cells and colony-forming unit-granulocyte-macrophage (CFU-GM) colony assay. The lyophilized ODNs (100 nmol) were dissolved in the bone marrow cell suspensions. The cells were counted every 24 hours for 4 days using the trypan blue dye exclusion test. The control consisted of cells undergoing the same procedure, without addition of ODN. After 72 hours of liquid culture, an identical volume of cell suspension was removed from all the flasks and used for the colony assay. The cells were plated in agar (final concentration, 0.33%) and Iscove's modified Dulbecco's medium (IMDM; GIBCO-BRL) supplemented with 25% fetal calf serum, 100 mmol/L 2-mercaptoethanol, 5% medium conditioned by the bladder carcinoma cell line 5637 as a source of growth factors and 10 ng/mL rhuIL-3. The semisolid assays were incubated in a humidified atmosphere with 5% CO2 at 37°C for 14 days. Colonies containing more than 50 cells were then scored.
RESULTS

Degradation of ODNs in serum.
We analyzed the kinetics of degradation of phosphodiester ODNs in culture media using a HPLC procedure. A typical chromatogram, presented in Fig 1, illustrates the observed 3' to 5 ' processive hydrolysis of the SB2A2 ODN. In media containing 2.5% to 10% fetal calf serum, the half-lives of phosphodiester ODNs are of about a few minutes (data not shown). On the contrary, in media containing 2.5% to 10% human serum, the halflives are 50 to 1 0 0 times longer (Table 1) . In both sera, the half-lives were found to be dependent on the nature of the 3' cleaved link. expressing the B2A2 junction, with various ODNs. The HL60 cell line, which does not possess the BCWABL fusion gene, was used as control. Two antisense sequences were used (ASB2A2 and ASB3A2) specific, respectively, of the B2A2 or B3A2 junction of the BCWABL mRNA. The two corresponding sense ODNs (SB2A2 and SB3A2) and a scrambled ODN (PERBCRABL) were used as controls. We observed a cell growth reduction when we incubated the BV173 cell line (Figs 2 and 3 ) with ASB2A2 at a concentra- tion higher than 10 pmoVL. This effect was maximal between 72 and 96 hours and decreased after 120 hours. Between 10 and 25 pmol/L, the effect appeared to be junctionspecific. At higher ODN concentrations, the B2A2 versus B3A2 specificity was lost (Fig 3) . The control ODNs (SB2A2 and PERBCRABL) were ineffective on the BV173 cell line at concentrations of up to 100 p m o K (data not shown). On the contrary, the HL60 cell line was refractory to any antiproliferative effect at ODN concentrations of up to 50 pmol/L (Fig 4) . ASB2A2 lost its antiproliferative effect on BV173 if the incubation medium contained fetal calf serum instead of human serum (data not shown). We incubated two other B2A2 (KCL22 and KYOl) and two B3A2 (LAMA84 and K562) cell lines with increasing concentrations of ASB2A2, ASB3A2, and sense control ODNs. Among all the tested cell lines, only KCL22 showed a cell growth reduction when incubated with ASB2A2 at a concentration of 50 pmol/L (Fig 4) .
Assessment of the specificiv of the efSect using control ODNs. To understand whether the small but reproducible effect of ASB3A2 at 50 pmoVL on BV173 could be due to its 9 ABL bases shared with ASB2A2, we designed two new 18-mer ODNs, ie, B2PERBCR and B2PERABL, that shared 9 bases with ASB2A2 (the ABL and the BCR bases, respectively). Their other 9 bases (the BCR bases for B2PERBCR and the ABL bases for B2PERABL) were scrambled. All the experiments described in this section were performed at ODN concentration of 25 pmol/L (Fig 5) . Surprisingly, B2PERABL produced the same antiproliferative effect as ASB2A2, whereas B2PERBCR was ineffective, showing that the antiproliferative effect could be attributed to the 9 BCR bases only. To further examine which sequence, if any, within the 9 BCR bases stretch was responsible for this effect, we synthesized 4 new 18-mer ODNs (TOXI, TOX2, TOX3, and TOX4). These ODNs were of random base comuse only. After incubation experiments performed with these ODNs, the 3' terminal TAT motif was found to be necessary and sufficient to induce a full antiproliferative effect.
To characterize the role of the TAT sequence, while ruling out a potential destabilizing effect of a single base change, we generated 3 ODNs (ASMB2A2, ASMI, and ASME) carrying a single mismatch at three different base positions of ASB2A2. Whereas ASMI and ASME conserved the typical antiproliferative effect, ASMB2A2 (in which the A of the TAT sequence was replaced with a C) lost it. Finally, to ascertain the role of the TAT motif, we changed the last 3' bases of the sense ODN (SB2A2) transforming the terminal TTC into a TAT (SMB2A2). This small change made SMB2A2 fully effective in terms of cytotoxic activity.
Having characterized the role of the terminal TAT motif on BV173 cell line, we tested KCL22 and HL60 cells with the same control ODNs. No difference between the effect of ASB2A2 and the effect of ODNs ending with TAT could be shown. If ASB2A2 had a antiproliferative effect (KCL22), the other "TAT" ODNs have the same effect. If ASB2A2 had no effect (HL60). the control ODNs did not affect the target cell either.
Efect of ASB2A2 and ODNs with a terminal TAT motif on fresh CML and normal CD34' cells. To answer the question of whether this cytotoxic nonantisense but sequence specific effect was also observed on fresh bone marrow cells and whether it was leukemia-restricted or not, we performed the same type of experiments on CD34' cells, either from CML or from healthy volunteers. Irrespective of the source (normal or leukemic), cell counts always displayed the same profile (Fig 6) . The SB2A2 oligomer had no effect in comparison with the control culture. ASB2A2 inhibited the pro- liferation of normal and CML marrow by 50% to 75% after 72 hours and the same result was achieved with TOXl. ASB3A2 had an intermediate effect, with a cell proliferation reduction of 25% to 30%.
To confirm that the effect shown in liquid culture occurred at the progenitor level, the cells were plated after 72 hours of liquid culture in a CFU-GM assay. The results of these colony assays were parallel to those of liquid cultures at 72 hours. The number of colonies was strictly proportional to the cell concentration in the aliquot taken for plating, showing that no further antiproliferative effect occurred during the 14 days of culture and that the observed effect had happened also in the progenitor compartment.
DISCUSSION
Caution is required when interpreting anti-BCWABL antisense studies. Direct comparison between all the published data is difficult because of the variety of experimental systems used to examine an antisense effect. Two recent studout the nonspecificity of the inhibition of CML cell line growth by phosphorothioate anti-BCWABL antisense ODNs. The relationship, if any, between the observed antiproliferative effect and the sequences of the tested phosphorothioate ODNs remains to be elucidated. 18-mer phosphodiester antisense ODNs, targeted to the BCWABL mRNA junctions, are described to inhibit the growth of several CML cell lines or to reduce the clonogenic capacity of leukemic hematopoietic progenitors from the bone marrow of CML patients. It is sometimes difficult to prove unequivocally the existence of antisense effects. We therefore decided to analyze the mechanism of this supposed antisense effect of anti-BCWABL phosphodiester ODNs, paying special attention to the ODNs used as controls.
Phosphodiester ODNs are known to be prone to enzymatic Among all the tested cell lines, only KCL22 and BV173 were sensitive to antisense ODNs that cause a reduction of cell growth. w e cannot observe any relationship between an antiproliferative effect and the cell lineage (lymphoid or myeloid), the type of junction (B2A2 or B3A2), or a defective expression of the normal ABL gene (BV173, LAMA84, and KYOl do not express the normal ABL gene). The observed antiproliferative effect of ASB2A2 phosphodiester ODN on BV173 and KCL22 cell lines cannot be attributed to an antisense mechanism. The TAT sequence at the 3' end of ASB2A2 seems responsible for the effect. A l-base mutation within this TAT motif abolishes the effect; several base mutations at any other position within the ASB2A2 sequence do not. We cannot differentiate the effect of ASB2A2 and the effect of ODNs with a TAT sequence at their 3' end. When ASB2A2 causes an effect, control ODNs with the TAT motif have the same effect. The mild but reproducible effect observed with ASB3A2 at 50 pmoUL cannot be explained by the TAT motif and is to be further examined.
On fresh bone marrow cells, ASB2A2-or TAT-containing ODNs induce the same effect, at the same concentration, irrespective of the fact that the cells are normal or leukemic and, in the latter case, of the type of junction. These experiments, together with the recently published data on phosphorothioate ODNS;~." strongly question the use of anti-BCW ABL ODNs as purging agents in CML.
Nonspecific effects have been already described with phosphodiester ODNs, particularly on hematopoietic cells. The mononucleotidic degradation products of ODNs may be cytotoxic:' Sequence-specific but nonantisense effects have also been reported with phosphodiester ODNs; palindromic sequence^^'"^ or sequences containing a CpG dinucleotidez6 
